BML Investment Partners, L.P. filed a Schedule 13G with the SEC on November 4, 2026, disclosing beneficial ownership of 2,110,727 shares of LENZ Therapeutics, Inc. common stock, representing 6.7% of the class, as of a triggering event dated November 2, 2026.

Key Highlights

  • Filer: BML Investment Partners, L.P., a Delaware limited partnership headquartered at 65 E Cedar - Suite 2, Zionsville, IN.
  • Shares beneficially owned: 2,110,727 shares of LENZ Therapeutics common stock, $0.00001 par value per share.
  • Percent of class: 6.7% as reported in the filing.
  • Voting and dispositive power: All 2,110,727 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
  • Triggering event date: November 2, 2026, per the filing.
  • Signing authority: Braden M. Leonard, Managing Member of BML Capital Management, LLC, the general partner of BML Investment Partners, L.P.

BML Investment Partners Reports Passive Ownership Position in LENZ Therapeutics

According to the Schedule 13G filed November 4, 2026, BML Investment Partners, L.P. reported beneficial ownership of 2,110,727 shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) common stock, with a par value of $0.00001 per share (CUSIP 52635N103). The filing identifies LENZ Therapeutics, Inc. as the issuer, with principal executive offices located at 201 Lomas Santa Fe Dr., Suite 300, Solana Beach, California 92075.

The filing discloses that BML Investment Partners holds all reported shares with shared voting power and shared dispositive power, while sole voting power and sole dispositive power are each listed as zero. The aggregate beneficial ownership of 2,110,727 shares represents 6.7% of the class, according to the filing. The statement was signed by Braden M. Leonard in his capacity as Managing Member of BML Capital Management, LLC, acting as general partner of BML Investment Partners, L.P.

In the certification included in the filing, BML Investment Partners stated that, to the best of its knowledge and belief, "the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11."

What Was Disclosed

BML Investment Partners, L.P. filed a Schedule 13G disclosing passive beneficial ownership of 2,110,727 shares, or 6.7%, of LENZ Therapeutics, Inc. common stock, with all shares held under shared voting and shared dispositive power as of November 2, 2026.